MUSK and myasthenia gravis: Phase III: all five (100%) MuSK autoantibody-positive patients in the rozanolixizumab 7 mg/kg group and all seven (100%) patients in the rozanolixizumab 10 mg/kg group were MG-ADL responders, compared to one (14%) of seven in the placebo group